Aclarion (NasdaqCM:ACON) Conference Transcript

Aclarion Conference Call Summary Company Overview - Aclarion (NasdaqCM:ACON) is a healthcare technology company focused on non-invasive diagnostic solutions for chronic low back pain, specifically through its product, NOSI scan [1][2] Industry Context - Chronic low back pain affects approximately 266 million people globally, contributing significantly to opioid addiction and leading to costly surgical interventions [3][4] - The lumbar fusion market in the United States is valued at $10 billion, with a broader market encompassing various invasive procedures estimated at $40 billion [5][6] Key Points and Arguments - Financial Position: Aclarion has zero debt, no preferred shares, and is fully compliant with Nasdaq requirements. The company has a cash burn rate of $2 million and a runway through 2027 [1][34] - Scan Volume Growth: The company has experienced consistent double-digit growth in scan volume over three consecutive quarters, supported by expanding physician referrals [1][2] - Clinical Evidence: Aclarion has funded a national randomized control trial (CLARITY trial) to validate the effectiveness of NOSI scan, with initial results from a previous trial showing a 97% positive outcome when surgery matched NOSI scan recommendations [2][19][20] - Market Opportunity: The company targets the largest single expenditure in healthcare, with a significant revenue opportunity in the lumbar fusion market alone estimated at $603 million [5][6][35] - Innovative Technology: NOSI scan utilizes MR spectroscopy to identify biomarkers in discs that cause pain, offering a non-invasive alternative to traditional, painful diagnostic methods [8][10][16] - Regulatory and Reimbursement Landscape: Aclarion has secured reimbursement from three of the top four payers in London, which is expected to drive adoption and growth in the U.S. market as well [26][27] Additional Important Insights - Intellectual Property: Aclarion holds 24 issued US patents and 17 international patents related to its technology, enhancing its competitive edge [14] - Management Team: The management team includes experienced professionals from the healthcare and technology sectors, which is expected to drive the company's strategic initiatives [32][33] - Future Catalysts: Key catalysts for growth include the results from the CLARITY trial, increased physician adoption, and ongoing marketing initiatives in both the U.S. and London [36] Conclusion - Aclarion is positioned to capitalize on a significant market opportunity in chronic low back pain diagnostics through its innovative NOSI scan technology, backed by strong clinical evidence and a solid financial foundation [35][36]